Keywords: ARIAD Pharma, Out-licenisng, ARGENT cell-signaling technology, Research reagents

ARIAD in three exclusive out-licensing deals for ARGENT cell-signaling regulation technology

Article | 21 April 2011

USA-based ARIAD Pharmaceuticals (Nasdaq: ARIA) has announced execution of three exclusive out-license agreements for separate aspects of its ARGENT cell-signaling ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Ariad Pharmaceuticals

Go to company listing